Medical/Pharmaceuticals Global News & Press Release Distribution

Medical/Pharmaceuticals

All
APAC

GCCL Completes Proactive Development of Biosimilar Clinical Trial Analysis Methods, Providing Customized Analysis Services through Enhanced R&D Capabilities

* Newly established R&D division this year is expected to provide full-scale in-house R&D in addition to clinical sample analysis * Including blockbuster drugs such as 'Keytruda' and 'Yervoy', GCCL offers tailored clinical trial analysis services for biosimilar development YONGIN, South Korea...

2024-07-17 10:38 2638

Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors

Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' radiopharmaceutical compound into an innovative anti-cancer treatment for worldwide markets HEIDELBERG, Germany and SEOUL, South Korea, July 16, 2024 /PRNewswire/ ...

2024-07-17 10:00 2692

Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery, Upcoming Webinar Hosted by HitGen and Xtalks

CHENGDU, China, July 16, 2024 /PRNewswire/ -- "Evolving DNA-Encoded Library Technology and Its Application for Innovative Drug Discovery" webinar will be jointly hosted by HitGen Inc. and Xtalks onWednesday July 17, 2024, at 2pm EDT ( 11am PDT). Alex Shaginian, PhD, Vice President of Business Deve...

2024-07-16 23:55 3590

FDA Grants Orphan Drug Designation to 7MW3711

SHANGHAI, July 16, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel B7-H3-targeting ADC (R&D code: 7MW3711) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...

2024-07-16 22:00 3100

Sanyou Bio Collaborates on ADC Drug Development Entering Phase I Clinical Trials

SHANGHAI, July 16, 2024 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine C...

2024-07-16 20:00 2881

Mabwell Receives NMPA Approval for Clinical Trial of Novel Nectin-4 Targeting ADC in TNBC

SHANGHAI, July 15, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821) has been approved by the NMPA to enter Phase II clinical trial as monotherapy or in combination with a PD...

2024-07-15 22:00 2862

United Imaging Announces First PET/CT Installation in Mexico, at Instituto Nacional de Pediatría

MEXICO CITY, July 15, 2024 /PRNewswire/ -- United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has launched its uMI 550 PET/CT system at the Instituto Nacional de Pediatría (INP) inMexico. This partnership reflects a shared commitment between the two organizati...

2024-07-15 20:00 2086

HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

ROCKVILLE, Md. and SEOUL, South Korea, July 15, 2024 /PRNewswire/ -- HanAll Biopharma (KRX: 009420.KS) announced today the appointment ofChristopher W. Slavinsky as Chief Business Development and Legal Officer. HanAll Biopharma Appoints Christopher...

2024-07-15 19:00 3223

HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

Nona Biosciences Enters into Collaboration Agreement with Alaya.bio to Advance CAR-T Cell Therapy

CAMBRIDGE, Mass., July 14, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a collaboration a...

2024-07-15 10:12 2132

Qilian International Holding Group Ltd Regained Compliance with Nasdaq's Minimum Bid Price Rule

CHENGDU, China, July 12, 2024 /PRNewswire/ -- Qilian International Holding Group Limited (NASDAQ: QLI) ("Qilian" or the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that onJuly 10, 2024, NASDAQ notified the Company that it has determined that for the...

2024-07-12 20:30 7427

Senhwa Biosciences Clinical Data Abstract of Pidnarulex Accepted for Presentation at 2024 ESMO Congress

TAIPEI and SAN DIEGO, July 12, 2024 /PRNewswire/ -- Senhwa Biosciences' new drug Pidnarulex (CX-5461) has demonstrated efficacy in treating various solid tumors with BRCA2 or PALB2 gene defects. The abstract of this clinical trial has been selected for presentation at the 2024 European Society fo...

2024-07-12 19:00 6167

CONCORD MEDICAL ANNOUNCES PLAN TO IMPLEMENT ADS RATIO CHANGE

BEIJING, July 11, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that it plans to change the ratio of its American d...

2024-07-12 04:00 5311

Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation

SEOUL, South Korea, July 11, 2024 /PRNewswire/ -- Medit, a global leader in dental 3D scanners and digital dentistry solutions, has appointedHan Ryu as its new CEO. Ryu brings with him over three decades of senior management experience in global medical device and healthcare companies, including ...

2024-07-11 21:00 4282

Medit Appoints Han Ryu as CEO, Focusing on Customer-Centric Innovation

First Patient Dosed in Phase I Clinical Trial of YOLT-201

SHANGHAI, July 11, 2024 /PRNewswire/ -- YolTech Therapeutics, a biotech company developing in vivo gene editing therapies to treat rare genetic diseases, announced today the successful enrollment of the first patient in the Phase I clinical trial of YOLT-201, its independently developed in vivo g...

2024-07-11 20:11 2702

Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC

SHANGHAI, July 11, 2024 /PRNewswire/ -- Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement. BioGeometry is a digital biology pioneer company that specializes in AI-driven protein design and R&D platform. Sanyou Bio is a world-leading high-tech...

2024-07-11 20:00 3632

Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL)

Initiation of cell therapy research and development program for adult T-Cell leukemia / lymphoma (ATLL) TOKYO, July 11, 2024 /PRNewswire/ -- The National Cancer Center (Tokyo, Japan ) and TheUniversity of Pennsylvania (Philadelphia, PA, USA) have licensed patent rights directed to a chimeric...

2024-07-11 14:21 2996

ADM Korea Announces Niclosamide-based Metabolic Anticancer Drug's First Clinical Trial Target as 'Prostate Cancer Patients Resistant to Hormone Therapy'

* IND for clinical study for combination therapy with hormone therapy in prostate cancer patients to be submitted in August, 2024. * Niclosamide-based metabolic anticancer drug aims to block signaling pathways that allow cancer cells to evade anticancer effects, potentially solving the issue ...

2024-07-11 14:07 3376

WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of the FTSE4Good Index Series. This marks the fourth consecutive year t...

2024-07-10 13:30 5052

WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year

Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development

CHONGQING, China, July 8, 2024 /PRNewswire/ -- Porton J-STAR today announced that Enabling Technologies Consortium (ETC) has awarded a two-year contract to J-STAR to collaborate on "Co-processing Platform Technology." The primary goal of co-p...

2024-07-08 22:00 2923

Porton J-STAR and Enabling Technologies Consortium Collaboration on Co-processing Platform Technology Development

Alteogen Receives Ministry of Food and Drug Safety (MFDS) Approval for Tergase®

* Tergase® poised to capture a fair share of the global hyaluronidase market. DAEJEON, South Korea, July 8, 2024 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced that the Ministry of Food and Drug Safety (MFDS) of Korea approved its New Drug Application (NDA...

2024-07-08 21:00 5521

1 ... 125 126 127128129 130 131 ... 264